Clarity Pharmaceuticals Ltd CU6
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CU6 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- A$2.71
- Day Range
- A$2.70–2.80
- 52-Week Range
- A$0.67–3.05
- Bid/Ask
- A$2.69 / A$2.80
- Market Cap
- A$836.90 Mil
- Volume/Avg
- 733,407 / 536,314
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
Comparables
Valuation
|
Metric
|
CU6
|
VCYT
|
TUB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 25.45 | 46.49 |
Price/Book Value | 6.89 | 1.35 | 2.27 |
Price/Sales | — | 3.86 | — |
Price/Cash Flow | — | 28.83 | — |
Price/Earnings
CU6
VCYT
TUB
Financial Strength
|
Metric
|
CU6
|
VCYT
|
TUB
|
|---|---|---|---|
Quick Ratio | 7.76 | 4.19 | 0.01 |
Current Ratio | 11.76 | 4.66 | 0.01 |
Interest Coverage | — | −5,596.07 | 27.75 |
Quick Ratio
CU6
VCYT
TUB
Profitability
|
Metric
|
CU6
|
VCYT
|
TUB
|
|---|---|---|---|
Return on Assets (Normalized) | −40.79% | 7.85% | −0.29% |
Return on Equity (Normalized) | −44.94% | 8.41% | −0.30% |
Return on Invested Capital (Normalized) | −47.32% | 7.64% | −0.12% |
Return on Assets
CU6
VCYT
TUB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qbpwzdkm | Zcqlw | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bxmxkhj | Wrhsnv | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ybjpfzty | Fmgdyz | $98.1 Bil | |
MRNA
| Moderna Inc | Ydqzwggvs | Gwjn | $38.8 Bil | |
ARGX
| argenx SE ADR | Ffjzgynk | Mhzt | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Hqbpvznm | Lcgg | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jdfxhlbt | Szntkd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dbrznfyf | Swmbzj | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Myxrlqgyc | Jmgynb | $12.5 Bil | |
INCY
| Incyte Corp | Nfkfgyym | Hcrhjl | $11.9 Bil |